Analysis
Clinical ink announced new equity investments from Ardan Equity, through its newly formed Ardan Equity Fund I, and GI Partners, through GI Partners Fund VI, in a co-control partnership, according to PR Newswire. GI Partners Fund V and other existing investors fully exited their prior stakes in the deal, for which the companies did not disclose a price.
A continuation, not an exit
GI Partners first invested in Clinical ink in 2020 and has backed the company since, a period in which Clinical ink grew revenue, expanded into new therapeutic areas, deepened relationships with preferred pharma providers, and launched its GlucoseReady and SPUR products. "We are pleased with the performance of the company since our 2020 investment," said Dave Kreter, GI Partners' managing director and head of healthcare. Rather than selling out entirely, GI Partners is rolling its stake from Fund V into Fund VI alongside new co-control partner Ardan Equity -- a continuation structure private equity firms increasingly use to keep backing a winning portfolio company past a single fund's typical hold period, without forcing a full sale to a third party.
Clinical ink, based in Winston-Salem, North Carolina with offices in Iowa, Pennsylvania and Copenhagen, supplies electronic clinical outcome assessment (eCOA) technology, connected devices and other eClinical tools that let pharmaceutical companies and contract research organizations capture clinical trial data, and has more recently expanded into clinical care disease management through its Kaitality application. For Ardan Equity, a healthcare-and-life-sciences-focused PE firm founded in 2019 and based in Palm Beach, Florida, Clinical ink is its first deal out of Ardan Equity Fund I and its eighth platform investment since 2020. Ardan managing partner Noah Lewis said the firm believes Clinical ink is at a key inflection point.
What the headline misses: no deal value was disclosed, which is standard for PE co-control and continuation transactions but means there's no public benchmark for how Clinical ink's valuation has moved since GI's 2020 entry. The eCOA and broader eClinical software category Clinical ink competes in -- against Medidata (owned by Dassault Systèmes), Veeva Systems, and Signant Health -- has consolidated around a small number of platforms as pharma sponsors standardize which vendors they'll certify for trial data capture, making scale and existing sponsor relationships, more than new technology, the main competitive edge left to fight over.